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Edited by Jesus AvilaAbstract We report that a mutant of human steﬁn B is in a
molten globule conformation. It has all the spectroscopic charac-
teristics for such a state. We also demonstrate that the molten
globule is oligomeric, eluting on SEC within a similar MW range
than the higher order oligomers of the wild type protein, which is
conﬁrmed by DLS and AFM. Both, the higher oligomers and the
molten globule state bind ANS, implying a high degree of hydro-
phobic patches exposure and partial opening of the structure.
Finally, we demonstrate that the oligomeric molten globule is
as toxic as the preﬁbrillar aggregates obtained at acid pH or
the higher order oligomers prepared at neutral pH.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Protein aggregation1. Introduction
Human steﬁn B (also termed cystatin B) is a member of the
family of cystatins, the cysteine protease inhibitors [1], a family
in the IH clan of proteases as classiﬁed by MEROPS [2]. Hu-
man cystatin C is a well-known amyloidogenic protein, causing
amyloid pathology with mutant L68Q observed in hereditary
cystatin C amyloid angiopathy (HCCAA) [3]. Mutations in
the human cystatin B gene cause EPM1, also known as Unver-
richt Lundborg disease [4]. On the basis of their in vitro behav-
iour [5], a hypothesis was formulated that some of the EPM1
mutants, those aﬀecting exonic parts of the gene, may aggre-
gate in the cell and thus cause some of the symptoms [6]. How-
ever, the present study is not meant to clarify possible
physiological function(s) of steﬁn B oligomers. It rather aims
to contribute to understanding of the common properties of
amyloidogenic proteins.
Protein folding to an alternative, amyloid precursor state
leads to protein aggregation [7–9]. Amyloid aggregates are ob-
served in various amyloidoses, among them a prominent class
of neurodegenerative diseases [10]. In Alzheimers disease (AD)
amyloid plaques, made predominantly of the cleavage product
amyloid-b (A-b), deposit in the brain, whereas the paired heli-Abbreviations: AFM, atomic force microscopy; DLS, dynamic light
scattering; SEC, size-exclusion chromatography
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accumulate intraneuronally [11]. In Huntingtons disease, hun-
tingtins aggregates cause slowing of the axonal transport
along microtubules [12,13] and in Parkinsons disease Lewy
bodies are found in the aﬀected neurons [11]. Familial cases
and animal models demonstrate that certain protein mutants
which lead to more heavy aggregation in vitro also lead to
early outburst of the disease [14,15], therefore, they are likely
the primary cause [11].
More and more evidence is being gathered that preﬁbrillar
oligomers/aggregates appearing with amyloidogenic proteins
in vitro [16,17] and in vivo [18] are cytotoxic. Toxicity is not
restricted to pathological proteins, it rather stems from some
common structural (conformational) characteristics of the pre-
ﬁbrillar oligomers [19,20]. An anti-amyloid antibody raised
against one preﬁbrillar oligomer was shown to bind oligomers
of a number of other amyloidogenic proteins [21]. Therefore,
even a non-pathological protein, such as steﬁn B, makes a
good model system to study toxicity. Human steﬁn B is prone
to form amyloid ﬁbrils under mildly acidic conditions and it
has served as an appropriate model protein in our in vitro
studies of amyloid ﬁbril formation [22–26].
In the era of the ‘‘protein folding problem’’ in the 1990s the
molten globule state was proposed as a general folding inter-
mediate [27,28]. The main characteristics of the molten globule
are high amount of secondary structure (not necessarily native)
and less rigid tertiary structure. This reﬂects in absent or low
near UV CD, low dispersion and broader peaks in NMR
and high propensity to bind ANS [28,29]. It seems likely that
this intermediate state, which has broken tertiary structure
contacts and exposed hydrophobic surfaces, would play a role
at the cross-road between folding and amyloid-ﬁbril forma-
tion.
It has been shown that proline 74 in the P79S mutant of the
steﬁn B iso-form harbouring a Y at site 31 and adopting a tet-
rameric state, is in a cis conformation [30]. We also know from
previous studies that mutation P74S on the backbone of the
Y31 iso-form (from now on P74S(Y31) mutant) leads to a mol-
ten globule state [31]. For this work, we characterised further
this mutant by using CD, ANS ﬂuorescence and 1D NMR,
conﬁrming its molten globule characteristics. In order to deter-
mine its oligomeric state, dimensions and morphology, SEC,
DLS and AFM were used.
In our previous studies, using our model system: human ste-
ﬁn B, we characterised the morphology, toxicity and membrane
interaction of preﬁbrillar oligomers/aggregates obtained at pH
values of 3 and 5 [22–26,32]. In this study, we compare
conformation of the higher order oligomers obtained at pH 7,
which were shown of similar toxicity than the preﬁbrillarblished by Elsevier B.V. All rights reserved.
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meric molten globule state, which also proves toxic.2. Materials and methods
2.1. Chemicals
CellTiter 96 AQueous One Solution Cell Proliferation Assay (a)
was from Promega. This is a reagent for colorimetric determination
of the number of viable cells in proliferation or cytotoxicity assays.
It contains tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt;
MTS] and electron coupling reagent (phenazine ethosulfate; PES).
Fluorogenic substrate Ac-DEVD-AFC for determining caspase-3-like
activity was from Bachem. Bradford assay was from Bio-Rad 1, anili-
no-naphthalene 8-sulfonate (ANS) was purchased at SERVA, Heidel-
berg, GE. Thioﬂavin T (ThT) was from Aldrich, Milwaukee, WI,
USA, and 2,2,2-triﬂuoroethanol (TFE), >99% pure was from Fluka,
Buchs, CH. All other chemicals were of analytical grade. Double dis-
tilled water was used and solvents were ﬁltered through 0.22 lm ﬁlters.
2.2. Protein isolation
The recombinant steﬁn B, the usual iso-form with tyrosine at site 31
was prepared as described [33,34]. Puriﬁcation steps consisted of CM-
papain Sepharose aﬃnity chromatography and gel-ﬁltration on Seph-
acryl-200 (Amersham-Pharmacia, Uppsalla, Sweden). The P74S(Y31)
mutant, which is inactive, was prepared by two-gel ﬁltration steps. Pro-
tein concentration was evaluated using an extinction coeﬃcient of
0.48 ml mg1 at 280 nm.
2.3. Preparation of the preﬁbrillar aggregates at pH 3
Preparation procedures and buﬀers were exactly the same as those
described [24,26]. Brieﬂy, proteins were incubated in in 0.015 M glycine
of pH 3.3 (0.26 M sodium sulfate) for 24–48 h, at room temperature.
2.4. Size exclusion chromatography (SEC)
The higher order oligomers StBpH7 and the molten globule state
P74S(Y31) were analyzed by the size exclusion chromatography
(SEC) using Superdex 75 and Superdex 200 (Amersham-Pharmacia
Biotech) columns on an AKTA FPLC system (Amersham-Pharmacia
Biotech). Before injection, all samples were ﬁltered through a 0.2 lm
ﬁlter (Sartorius Minisart). The mobile phase was 0.01 M phosphate/
0.15 M NaCl at pH 7, the ﬂow rate was set at 0.5 ml/min, and the elu-
tion peaks were detected by absorbance at 280 nm.
2.5. MTS reduction assay
Cytotoxicity was determined by the MTS reduction assay. SH-SY5Y
cells were plated onto 96-well plates at a density of 10000 cells per well
in 100 ll fresh medium. To probe cellular toxicity, 20 ll of concen-
trated (120 lM) preﬁbrillar aggregates of pH 3 (and neutralized), oligo-
mers separated at pH 7 and the molten globule P74S(Y31) at pH 7
were added to 96-well plates. Buﬀer alone, non-amyloidogenic steﬁn
A, and staurosporine were added to separate wells as controls. After
an overnight incubation at 37 C in a 5% CO2 humidiﬁed environment,
20 ll of MTS was added to each well and the plates were incubated for
an additional 2–3 h. After solubilization, the absorbance of the forma-
zan product was measured at 490 nm using an automatic plate reader.
2.6. Caspase-3-like activity
Caspase-3-like activity was measured by the DEVD (Bachem) assay,
in which Ac-DEVD-AFC is a ﬂuorogenic substrate cleaved by caspase-
3 but also by several other caspases. SH-SY5Y cells were plated onto
12-well plates and incubated to 80–90% conﬂuent density. Two hun-
dred microliter of concentrated preﬁbrillar aggregates of pH 3
(StBpH3) or P74S(Y31) mutant was added to 800 ll of complete cell
medium. After treatment, aliquots of cell lysates (50 lg of protein as
determined by Bradford assay) of untreated and treated cells were used
to determine the caspase activity.
2.7. CD spectroscopy
CD spectra were measured using an Aviv model 62ADS CD spectro-
polarimeter equipped with a thermoelectric sample holder for temper-ature control in the cell. To record far- and near-UV CD spectra,
bandwidths were set at 1 nm and 0.5 nm for 0.1 cm and 1 cm cells,
respectively. Data in the far-UV were collected every 1 nm and in
the near-UV every 0.5 nm. Averaging times were 5 s and 3 s for the
far- and near-UV, respectively. Temperature was maintained at
25 C throughout. Protein concentration of P74S(Y31) was 1.6 mg/
ml (145 lM) for the near UV and 0.33 mg/ml (30 lM) for the far
UV. Concentrations of other variants were the same in molar terms.
2.8. ANS ﬂuorescence measurement
Fluorescence was measured using a Perkin–Elmer model LS 50 B
luminescence spectrometer. Excitation was at 370 nm, emission spectra
were recorded from 400 to 600 nm using a 0.5 cm cell. ANS concentra-
tion in the buﬀer for dilution (0.01 M phosphate, 0.15 M NaCl, pH 7)
was 1.5 mM. Proteins: P74S(Y31) steﬁn B (the oligomeric molten glob-
ule state) and the isolated oligomers of the wild type, initially at 57 lM
and 75 lM, respectively, were diluted 1:3, to the ﬁnal ANS concentra-
tion of 1 mM. Resulting protein concentrations were: 19 lM for the
P74S(Y31) and 25 lM for the w.t. oligomers. Protein concentration
of P74S(Y31) was also varied from 12 lM to 25 lM at the same ﬁnal
ANS concentration, which represented ratios ANS:protein from 80 to
42.
2.9. Atomic force microscopy (AFM)
The P74S(Y31) mutant was unfrozen from a batch at 120 lM and
ﬁltered through 0.2 lm ﬁlter (Sartorius Minisart). After a 10-fold dilu-
tion, a 20 ll of protein sample was mounted onto a freshly cleaved
mica surface (1 cm2) incubated for 5 min and gently washed with the
solvent or deionized water. Excess solvent was removed with a stream
of nitrogen. Images were obtained with a Nanoscope III Multimode
scanning probe microscope (Digital Instruments) operated in tapping
mode.
In more detail: scan rate was 1 Hz and tip oscillation rate was 170–
180 kHz. Silicon doped cantilevers were from nanosensors (nodel
NCLR). Pixel resolution was 512 · 512. Scanner E was from Digital
Instruments (12 · 12 lm) and approximate tip diameter was 10–
15 nm. Polynomial line ﬂattening was used after obtaining raw image
data.
2.10. Dynamic light scattering (DLS)
DLS measurements were performed at room temperature using
PDDLS/BatchPlus System (Precision Detectors). All buﬀers used were
ﬁltered using Centriprep YM 50 ﬁlters (Amicon). The sample of the
oligomeric molten globule P74S(Y31) was taken from the same batch
as for AFM and was ﬁltered through 0.2 lm ﬁlter (Sartorius Minisart).
Higher order oligomers were collected from SEC and used as such.
Before measurements all samples were brieﬂy centrifuged. A 400 ll
sample was inserted in a quartz cuvette. A run time of 1 s and sampling
time of 5 ls were set. Typically, at least 50 accumulated correlation
functions were used to to calculate the diameter of scattering particles
using the PrecisionDeconvolve software provided by the manufacturer.
Scattering peaks of <0.1 nm radius and more than 1000 nm were
ignored.3. Results
3.1. Oligomeric state, size and toxicity of the molten globule
By using size-exclusion chromatography (SEC) Superdex 75
column we isolated higher order oligomers of steﬁn B wild
type, higher than the tetramers. When these were applied to
Superdex 200 column they eluted as a broad peak covering
66–350 kDa, corresponding to 6-mers to 32-mers, with pre-
dominant peak apparently at the 12-mers (Fig. 1A). When
the molten globule P74S(Y31) was applied on the same col-
umn, the elution was similar to the higher oligomers of the
wild type (Fig. 1A).
To characterise the oligomers further dynamic light scatter-
ing (DLS) was used. In a previous DLS study, hydrodynamic
radii of the isolated dimer and tetramer were determined as
2.9 nm and 3.5 nm, respectively [30]. In Fig. 1B, DLS measure-
Fig. 1. (A) Size exclusion chromatography – SEC on Superdex 200 column of the higher order oligomers of the wild type steﬁn B (StBpH7) and of
the molten globule mutant P74S(Y31). The mobile phase was phosphate 0.01 M sodium phosphate buﬀer, 0.15 M NaCl, pH 7. (B) Dynamic light
scatteing – DLS. Top – SEC isolated higher oligomers of the wild type steﬁn B (StBpH7) showing bimodal distribution of particle diameters. Bottom
– the oligomeric molten globule P74S(Y31); similarly showing a bimodal distribution.
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son to the isolated higher oligomers (higher panel) is shown.
DLS measurement of the higher oligomers resulted in a bimo-
dal distribution with approximately 79% of oligomers display-
ing average diameters ranging from 4.8 to 8.3 nm, while the
average diameters of the other 21% ranged from 30 to 88 nm
(see, H.olg.StBpH7 in Fig. 1B, top). Slightly diﬀerent distribu-
tion was observed for the molten globule sample with approx-
imately 40% of oligomers displaying average diameters rangingFig. 2. Atomic force microscopy – AFM images of the molten globule sam
isolated by gel ﬁltration on Sephacryl-200. Dilution to around 12 lM conce
images were taken in tapping mode with a Nanoscope III Multimode scanni
(A) A lower magniﬁcation to 2 lm. (B) An insert at higher magniﬁcation.from 14 to 24 nm, while the average diameters of the other
56% ranged from 50 to 88 nm (see, P74S(Y31) in Fig. 1B, bot-
tom). There was also a trace of particles smaller than 5 nm.
The dimensions obtained by DLS for the oligomeric molten
globule P74S(Y31) are consistent with the dimensions deter-
mined for the pH 3 preﬁbrillar aggregate [45], which initially
also is in a molten globule conformation [24,35].
By AFM (Fig. 2B and unshown data) the molten glob-
ule P74S(Y31) appeared as globular (elliptoid) oligomers withple. The sample of the P74S(Y31) mutant was unfrozen from a batch
ntration was performed by using double distilled Millipore water. The
ng probe microscope. For each image: height – left, amplitude – right.
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similarly to those of the preﬁbrillar aggregate of pH 3, where
an average value of 12.5 was determined before [26]. This ﬁts
well to the diameter observed by DLS for the major part of
oligomers (Fig. 1B, bottom). However, in addition to these,
one can detect particles of up to 100 nm lateral dimensions
and heights of 20 nm by AFM (Fig. 2A), again consistent with
a range of diameters seen by DLS (Fig. 1B, bottom).
In Fig. 3A and B are shown the results of the MTS and cas-
pase-3-like activity assays. To measure cell viability an MTS
assay was performed after incubation of SH-SY5Y cells for
16 h at 37 C with either acid-induced preﬁbrillar aggregates
or SEC separated higher-order oligomers diluted into the med-
ium of pH 7.3. There was no signiﬁcant diﬀerence in cytotox-
icity between acid-induced preﬁbrillar aggregates (neutralized
from pH 3 before dissolving into the medium), isolated higher
order oligomers, and the P74S(Y31) mutant, this latter adopt-
ing a molten globule conformation. The eﬀect observed with
44 lM oligomer or aggregate concentration was modest in
all cases, with 20–30% lower formazan production (Fig. 3A).
The pH 3 preﬁbrillar aggregates also caused a signiﬁcant
enhancement of DEVD activity, a measure for caspase-3-like
activity. Similar eﬀect was observed for the molten globule
P74S(Y31) oligomers (Fig. 3B).Fig. 3. Cell viability assays. (A) MTS reduction assay was performed
after cells were incubated in the cell medium with dissolved preﬁbrillar
aggregates of pH 3 (ﬁrst neutralized), SEC isolated higher order
oligomers and the molten globule mutant P74S(Y31). (B) DEVD
assay, which measures caspase-3-like activity, was performed for the
pH 3 preﬁbrillar aggregates (after being neutralized) and for the
oligomeric molten globule P74S(Y31).3.2. Structural/conformational characteristics of the toxic
oligomers
It is very diﬃcult to obtain structural data (using crystallo-
graphy or heteronucelar NMR) of the preﬁbrillar oligomers
and assemblies, due to inhomogeneity and mobility of such
samples. Steﬁn B tetramer structure in crystal and in solution
has been determined by Jenko Kokalj et al. [30] and the struc-
tures of the domain-swapped dimers of cystatins C and steﬁn
A (i.e., cystatin A) by Jaskolski et al., Staniforth et al.
[36,37], respectively. However, the lower oligomers including
the tetramer, do not show cytotoxicity [45].
To probe general structural characteristics, such as the sec-
ondary structure and surface exposure, CD and ANS ﬂuores-
cence emission spectra of the higher-order oligomers of the wt
and the oligomeric molten globule P74S(Y31) were deter-
mined. CD spectra of the preﬁbrillar aggregates accumulating
in the lag phase at pH 5 and 3 were reported before [24] and
were reminiscent of a native-like state and ‘‘structured molten
globule’’, respectively [35].
CD spectra of the P74S(Y31) mutant in the far UV (Fig. 4A)
and near UV (Fig. 4B) are ﬁrst compared to the corresponding
CD spectra of the parent steﬁn B (stB-Y31) and its P79S(Y31)
mutant, the latter forming a tetramer [30].
In Fig. 4C are shown the far UV CD spectra of separated
oligomers: monomers, tetramers and the higher oligomers, as
well as of the P74S(Y31) mutant, which shares a similar oligo-
meric state as the higher oligomers (Fig. 1A and B). In Fig. 4D
are shown ANS ﬂuorescence spectra upon binding of the dye
to the separated monomers, dimers, tetramers, higher oligo-
mers and the oligomeric molten globule P74S(Y31).
ANS dye was used to determine exposed hydrophobic
patches [29]. Molten globule state is known to bind ANS
extensively [28,29]. As seen from Fig. 4D, the isolated mono-
mer and dimer of the wild type protein do not bind ANS, tet-
ramer binds a little, whereas the higher oligomers bind quite
an amount. The oligomeric molten globule shows the highest
ANS binding (Fig. 4D). It is of note that the far UV CD
spectra of the higher oligomers of the wild-type do not
resemble the spectrum of the molten globule [35], they can
be described as ‘‘native-like’’. The peak at 225 nm, which
increases with oligomerization may be characteristic of the
tyrosine contribution towards the far UV CD [38]. It is not
surprising that tyrosine environment would change upon oligo-
merization.
1D NMR spectra of the P74S(Y31) mutant were also re-
corded (Fig. 4E) and are consistent with its molten globule
character, i.e., low dispersion of chemical shifts and broader
peaks than for completely denatured proteins, also character-
istic of the 1D NMR of steﬁn B at pH 3.4. Discussion
It seems logical and was in certain cases shown experimen-
tally, that partially unfolded states and folding intermediates
lye at the cross-road between folding and amyloid-ﬁbrillation
[7–9]. We are using human steﬁn B (cystatin B) as a model
amyloidogenic protein for quite some time [5,22–26,30,32],
and have shown that it shares most properties with other amy-
loidogenic systems. We recently have encountered on a muta-
tion P74S(Y31), which causes the protein to adopt a
‘‘structured’’ molten globule state already at neutral pH. In
Fig. 4. Conformational characterization of the molten globule. (A) Far UV CD spectra and (B) near UV CD spectra of the parent steﬁn B (stB-Y31),
the proline mutant P79S(Y31), which is tetrameric, and the P74S(Y31) mutant, which is molten globule and oligomeric. (C) Far UV CD spectra:
comparison of the spectrum of isolated monomer, dimer, tetramer and higher order oligomers of the wild type steﬁn B (stB-wt) in comparison to the
oligomeric molten globule P74S(Y31). (D) ANS binding to isolated monomers and oligomers of the wild type steﬁn B in comparison to the mutant
P74S(Y31), which is oligomeric molten globule. (E) 1H NMR spectrum of the oligomeric molten globule P74S(Y31). Protein concentration was
around 1 mM, buﬀer was 0.005 M sodium phosphate, 0.06 M NaCl, pH 6.3. The spectrum was taken using Brucker AMX-500 machine.
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what is very interesting by our opinion, toxic. To obtain an
answer to the question: ‘‘What is the conformation of toxic
oligomers of amyloidogenic proteins?’’, we measured general
spectroscopic properties of the oligomeric molten globule state
in comparison to the higher oligomers (higher than the tetra-
mer) of the wild type protein.
In our studies of amyloid ﬁbril formation of steﬁn B we have
observed that the protein can start ﬁbrillation directly from the
molten globule state at pH 3 (after a lag phase of 48 h at r.t.),
or it goes transiently through such a state in the early growth
phase at pH 5, 10% TFE [22,24]. We now came across an
observation that not only external denaturation can induce a
molten globule state but this also can happen upon suitable
mutation.
The induction of the molten globule intermediate at equilib-
rium is dependant on the proteins stability. The 31Y iso-form
of steﬁn B (our usual variant used in most folding studies so
far) is prone to undergo such a transition rather easily during
denaturation by chemical denaturants [39], acidic pH and tem-
perature [35]. The molten globule state is also attained by the
P74S mutant of the Y31 iso-form of the protein (termed
P74S(Y31)), already at neutral pH. Interestingly, the mutation
P74S in the wild type protein does not change conformation of
the folded protein (E.Zˇ., unpublished).
In this work, we compare conformational characteristics of
the molten globule state to the isolated higher oligomers ofthe wild type protein. We also show that both are toxic to cells.
However, to our surprise the molten globule mutant
P74S(Y31) was at least equally toxic than the higher oligomers
of the wild type (Fig. 3A). This became more understandable
when the mutant was applied to SEC. The elution of the mol-
ten globular P74S(Y31) mutant on SEC was even broader than
the higher order oligomers (Fig 1A), implying its oligomeric
nature.
One needs to be cautious when comparing native and molten
globule states on the basis of their elution by SEC. It is known
that molten globular state can show up to 20% increased
Stokes radius on gel ﬁltration [27]. It may sometimes appear
as a dimer, even though it could be a somewhat open mono-
mer. Therefore, it is important to use an alternative method.
We have chosen DLS (Fig. 1B) and conﬁrmed that the molten
globule is indeed oligomeric and prone to aggregate.
By AFM (Fig. 2B) the lateral dimension (diameter P 12 nm)
of the basic oligomeric unit in the molten globule P74S(Y31)
sample falls in between that of the isolated higher oligomers
and of the preﬁbrillar aggregates at pH 3 [26,45]. However,
there also are some bigger particles and aggregates present
(Fig. 2A), which explains the spread in the diameters obtained
by DLS.
From all the collected results, we can safely conclude that
the molten globule of P74S(Y31) is oligomeric and that it is
higher than the tetramer, which has a hydrodynamic radius
of 3.5 nm [30]. It also can be concluded that the oligomeric
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for protoﬁbrils or ﬁbrils. DLS measurement (lower panel in
Fig. 1B) and AFM (Fig. 2A) show particles with diameters
of up to 100 nm. These do not seem as chains of ‘‘globular
oligomers’’ but rather as an aggregate with heights of up to
20 nm as determined by AFM (Fig. 2A). In contrast, it was ob-
served before that the ‘‘globular oligomers’’ making the pH 3
aggregate were prone to chain up and start growing into pro-
toﬁbrils, both, by AFM and DLS [45].
Even though of similar toxicity, there are diﬀerences in con-
formation between the oligomeric molten globule P74S(Y31)
and the separated higher order oligomers of the wild type.
This is reﬂected in the CD spectra and ANS binding. The
CD spectra (Fig. 4C) of the higher order oligomers are still
‘‘native-like’’ whereas the ANS binding is increased
(Fig. 4D). The molten globule state P74S(Y31), on the other
side, has a characteristic far UV CD and very low near UV
CD (see, Fig. 4A–C), binds ANS to the highest level
(Fig. 4D) and shows broad resonances in 1D NMR with little
dispersion (Fig. 4E).
At ﬁrst glance, the toxicity of the separated higher oligomers
and the molten globule state (Fig. 3A and B) seem to correlate
with the ANS binding (Fig. 4D). On the basis of high ANS
binding (Fig. 4D), which is the highest for P74S(Y31), one
would expect even higher toxicity for the molten globule state.
This is not observed within experimental errors (Fig. 3A).
However, one cannot say with certainty if membrane compo-
nents themselves do not inﬂuence the initial ‘‘native-like’’ con-
formation of higher oligomers to change into molten globular
prior to binding. Role of the molten globule conformation as
the membrane binding conformation was suggested by Ptitsyn
and co-workers [40]. The questions of how ‘‘amyloid toxins’’
cross lipid-bilayers and if that resembles PFT (pore forming
toxins) remain to be seen.
It is to be mentioned that molten globule conformation
recently was found in prion oligomerization [41]. Our study
suggests that this could be a more common and even toxic con-
formation of amyloidogenic proteins.5. Conclusions
1. We believe that our ﬁnding that a mutant of steﬁn B, which
adopts an oligomeric molten globule state, is toxic, and that
its toxicity is similar to that of the isolated higher-order
oligomers, is signiﬁcant. It sheds some light on the question:
‘‘What is the conformation of toxic oligomers of amyloido-
genic proteins?’’ Part of the answer may be: ‘‘A more open
conformation, at least partially unfolded or molten glob-
ule.’’
2. The oligomeric molten globule accumulates in the form of
preﬁbrillar oligomers already at neutral pH and does not
proceed into amyloid ﬁbrils. Thus, alternative folding from
the molten globule might be needed for ﬁbril formation.
3. In view of the hypothesis that toxicity of amyloidogenic
proteins occurs via membrane permeation [42], our results
indicate that conformational change to a molten globule
state is suﬃcient and very likely a prerequisite for mem-
brane interactions and toxicity.
4. The same conformational change may happen to native-like
oligomers when they encounter membranes or, at the onsetof ﬁbril formation. We have observed a temporarily in-
creased CD at 222 and 208 nm (more a-helix) under ﬁbril
promoting conditions [24]. Temporarily increased helicity
was reported by some others [43] and by theoretical calcu-
lations [44].
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